WARNINGS O
Clinical O
Worsening O
and O
Suicide O
Risk O
Patients O
with O
major B-Not_AE_Candidate
depressive I-Not_AE_Candidate
disorder I-Not_AE_Candidate
( I-Not_AE_Candidate
MDD I-Not_AE_Candidate
) O
, O
both O
adult O
and O
pediatric O
, O
may O
experience O
worsening B-NonOSE_AE
of I-NonOSE_AE
their I-NonOSE_AE
depression I-NonOSE_AE
and/or O
the O
emergence O
of O
suicidal B-NonOSE_AE
ideation O
and O
behavior I-NonOSE_AE
( O
suicidality B-NonOSE_AE
) O
or O
unusual B-NonOSE_AE
changes I-NonOSE_AE
in I-NonOSE_AE
behavior I-NonOSE_AE
, O
whether O
or O
not O
they O
are O
taking O
antidepressant O
medications O
, O
and O
this O
risk O
may O
persist O
until O
significant O
remission O
occurs O
. O

Suicide B-NonOSE_AE
is I-NonOSE_AE
a O
known O
risk O
of O
depression B-Not_AE_Candidate
and O
certain O
other O
psychiatric B-Not_AE_Candidate
disorders I-Not_AE_Candidate
, O
and O
these O
disorders O
themselves O
are O
the O
strongest O
predictors O
of O
suicide B-NonOSE_AE
. O

There O
has O
been O
a O
long-standing O
concern O
, O
however O
, O
that O
antidepressants O
may O
have O
a O
role O
in O
inducing O
worsening B-OSE_Labeled_AE
of I-OSE_Labeled_AE
depression I-OSE_Labeled_AE
and O
the O
emergence O
of O
suicidality B-OSE_Labeled_AE
in O
certain O
patients O
during O
the O
early O
phases O
of O
treatment O
. O

Pooled O
analyses O
of O
short-term O
placebo-controlled O
trials O
of O
antidepressant O
drugs O
( O
SSRIs O
and O
others O
) O
showed O
that O
these O
drugs O
increase O
the O
risk O
of O
suicidal B-OSE_Labeled_AE
thinking O
and O
behavior I-OSE_Labeled_AE
( O
suicidality B-OSE_Labeled_AE
) O
in O
children O
, O
adolescents O
, O
and O
young O
adults O
( O
ages O
18-24 O
) O
with O
major B-Not_AE_Candidate
depressive I-Not_AE_Candidate
disorder I-Not_AE_Candidate
( I-Not_AE_Candidate
MDD I-Not_AE_Candidate
) O
and O
other O
psychiatric B-Not_AE_Candidate
disorders I-Not_AE_Candidate
. O

Short-term O
studies O
did O
not O
show O
an O
increase O
in O
the O
risk O
of O
suicidality B-NonOSE_AE
with O
antidepressants O
compared O
to O
placebo O
in O
adults O
beyond O
age O
24 O
; O
there O
was O
a O
reduction O
in O
risk O
with O
antidepressants O
compared O
to O
placebo O
in O
adults O
aged O
65 O
and O
older O
. O

The O
pooled O
analyses O
of O
placebo-controlled O
trials O
in O
children O
and O
adolescents O
with O
MDD B-Not_AE_Candidate
, O
obsessive B-Not_AE_Candidate
compulsive I-Not_AE_Candidate
disorder I-Not_AE_Candidate
( I-Not_AE_Candidate
OCD I-Not_AE_Candidate
) O
, O
or O
other O
psychiatric B-Not_AE_Candidate
disorders I-Not_AE_Candidate
included O
a O
total O
of O
24 O
short-term O
trials O
of O
9 O
antidepressant O
drugs O
in O
over O
4400 O
patients O
. O

The O
pooled O
analyses O
of O
placebo-controlled O
trials O
in O
adults O
with O
MDD B-Not_AE_Candidate
or O
other O
psychiatric B-Not_AE_Candidate
disorders I-Not_AE_Candidate
included O
a O
total O
of O
295 O
short-term O
trials O
( O
median O
duration O
of O
2 O
months O
) O
of O
11 O
antidepressant O
drugs O
in O
over O
77,000 O
patients O
. O

There O
was O
considerable O
variation O
in O
risk O
of O
suicidality B-OSE_Labeled_AE
among O
drugs O
, O
but O
a O
tendency O
toward O
an O
increase I-OSE_Labeled_AE
in O
the O
younger O
patients O
for O
almost O
all O
drugs O
studied O
. O

There O
were O
differences O
in O
absolute O
risk O
of O
suicidality B-NonOSE_AE
across O
different O
indications O
, O
with O
the O
highest O
incidence O
in O
MDD B-Not_AE_Candidate
. O

The O
risk O
differences O
( O
drug O
vs O
. O
placebo O
) O
, O
however O
, O
were O
relatively O
stable O
within O
age O
strata O
and O
across O
indications O
. O

These O
risk O
differences O
( O
drug-placebo O
difference O
in O
the O
number O
of O
cases O
of O
suicidality B-NonOSE_AE
per O
1000 O
patients O
treated O
) O
are O
provided O
in O
Table O
1 O
. O

Table O
1 O
Age O
Range O
Drug-Placebo O
Difference O
in O
Number O
of O
Cases O
of O
Suicidality B-OSE_Labeled_AE
per O
1000 O
Patients O
Treated O
Increases O
Compared O
to O
Placebo O
< O
18 O
14 O
additional O
cases O
18-24 O
5 O
additional O
cases O
Decreases O
Compared O
to O
Placebo O
25-64 O
1 O
fewer O
case O
> O
=65 O
6 O
fewer O
cases O
No O
suicides B-NonOSE_AE
occurred O
in O
any O
of O
the O
pediatric O
trials O
. O

There O
were O
suicides B-NonOSE_AE
in O
the O
adult O
trials O
, O
but O
the O
number O
was O
not O
sufficient O
to O
reach O
any O
conclusion O
about O
drug O
effect O
on O
suicide B-NonOSE_AE
. O

It O
is O
unknown O
whether O
the O
suicidality B-NonOSE_AE
risk O
extends O
to O
longer-term O
use O
, O
i.e. O
, O
beyond O
several O
months O
. O

However O
, O
there O
is O
substantial O
evidence O
from O
placebo-controlled O
maintenance O
trials O
in O
adults O
with O
depression B-Not_AE_Candidate
that O
the O
use O
of O
antidepressants O
can O
delay O
the O
recurrence O
of O
depression B-NonOSE_AE
. O

All O
patients O
being O
treated O
with O
antidepressants O
for O
any O
indication O
should O
be O
monitored O
appropriately O
and O
observed O
closely O
for O
clinical O
worsening O
, O
suicidality B-NonOSE_AE
, O
and O
unusual B-NonOSE_AE
changes I-NonOSE_AE
in I-NonOSE_AE
behavior I-NonOSE_AE
, O
especially O
during O
the O
initial O
few O
months O
of O
a O
course O
of O
drug O
therapy O
, O
or O
at O
times O
of O
dose O
changes O
, O
either O
increases O
or O
decreases O
. O

The O
following O
symptoms O
, O
anxiety B-OSE_Labeled_AE
, O
agitation B-OSE_Labeled_AE
, O
panic B-OSE_Labeled_AE
attacks I-OSE_Labeled_AE
, O
insomnia B-OSE_Labeled_AE
, O
irritability B-OSE_Labeled_AE
, O
hostility B-OSE_Labeled_AE
, O
aggressiveness B-OSE_Labeled_AE
, O
impulsivity B-OSE_Labeled_AE
, O
akathisia B-OSE_Labeled_AE
( O
psychomotor B-OSE_Labeled_AE
restlessness I-OSE_Labeled_AE
) O
, O
hypomania B-OSE_Labeled_AE
, O
and O
mania B-OSE_Labeled_AE
, O
have O
been O
reported O
in O
adult O
and O
pediatric O
patients O
being O
treated O
with O
antidepressants O
for O
major B-Not_AE_Candidate
depressive I-Not_AE_Candidate
disorder I-Not_AE_Candidate
as O
well O
as O
for O
other O
indications O
, O
both O
psychiatric B-Not_AE_Candidate
and O
nonpsychiatric O
. O

Although O
a O
causal O
link O
between O
the O
emergence O
of O
such O
symptoms O
and O
either O
the O
worsening B-NonOSE_AE
of I-NonOSE_AE
depression I-NonOSE_AE
and/or O
the O
emergence O
of O
suicidal B-NonOSE_AE
impulses I-NonOSE_AE
has O
not O
been O
established O
, O
there O
is O
concern O
that O
such O
symptoms O
may O
represent O
precursors O
to O
emerging O
suicidality B-NonOSE_AE
. O

Consideration O
should O
be O
given O
to O
changing O
the O
therapeutic O
regimen O
, O
including O
possibly O
discontinuing O
the O
medication O
, O
in O
patients O
whose O
depression B-Not_AE_Candidate
is O
persistently O
worse O
, O
or O
who O
are O
experiencing O
emergent O
suicidality B-NonOSE_AE
or O
symptoms O
that O
might O
be O
precursors O
to O
worsening B-NonOSE_AE
depression I-NonOSE_AE
or O
suicidality B-NonOSE_AE
, O
especially O
if O
these O
symptoms O
are O
severe O
, O
abrupt O
in O
onset O
, O
or O
were O
not O
part O
of O
the O
patient O
's O
presenting O
symptoms O
. O

Families O
and O
caregivers O
of O
patients O
being O
treated O
with O
antidepressants O
for O
major B-Not_AE_Candidate
depressive I-Not_AE_Candidate
disorder I-Not_AE_Candidate
or O
other O
indications O
, O
both O
psychiatric O
and O
nonpsychiatric O
, O
should O
be O
alerted O
about O
the O
need O
to O
monitor O
patients O
for O
the O
emergence O
of O
agitation B-NonOSE_AE
, O
irritability B-NonOSE_AE
, O
unusual B-NonOSE_AE
changes I-NonOSE_AE
in I-NonOSE_AE
behavior I-NonOSE_AE
, O
and O
the O
other O
symptoms O
described O
above O
, O
as O
well O
as O
the O
emergence O
of O
suicidality B-NonOSE_AE
, O
and O
to O
report O
such O
symptoms O
immediately O
to O
health O
care O
providers O
. O

Such O
monitoring O
should O
include O
daily O
observation O
by O
families O
and O
caregivers O
. O

Prescriptions O
for O
REMERON O
( O
mirtazapine O
) O
Tablets O
should O
be O
written O
for O
the O
smallest O
quantity O
of O
tablets O
consistent O
with O
good O
patient O
management O
, O
in O
order O
to O
reduce O
the O
risk O
of O
overdose B-NonOSE_AE
. O

Screening O
Patients O
for O
Bipolar O
Disorder O
A O
major B-NonOSE_AE
depressive I-NonOSE_AE
episode I-NonOSE_AE
may O
be O
the O
initial O
presentation O
of O
bipolar B-Not_AE_Candidate
disorder I-Not_AE_Candidate
. O

It O
is O
generally O
believed O
( O
though O
not O
established O
in O
controlled O
trials O
) O
that O
treating O
such O
an O
episode O
with O
an O
antidepressant O
alone O
may O
increase O
the O
likelihood O
of O
precipitation B-NonOSE_AE
of I-NonOSE_AE
a I-NonOSE_AE
mixed I-NonOSE_AE
/ I-NonOSE_AE
manic I-NonOSE_AE
episode I-NonOSE_AE
in O
patients O
at O
risk O
for O
bipolar B-Not_AE_Candidate
disorder I-Not_AE_Candidate
. O

Whether O
any O
of O
the O
symptoms O
described O
above O
represent O
such O
a O
conversion O
is O
unknown O
. O

However O
, O
prior O
to O
initiating O
treatment O
with O
an O
antidepressant O
, O
patients O
with O
depressive B-Not_AE_Candidate
symptoms I-Not_AE_Candidate
should O
be O
adequately O
screened O
to O
determine O
if O
they O
are O
at O
risk O
for O
bipolar B-Not_AE_Candidate
disorder I-Not_AE_Candidate
; O
such O
screening O
should O
include O
a O
detailed O
psychiatric B-Not_AE_Candidate
history O
, O
including O
a O
family B-Not_AE_Candidate
history I-Not_AE_Candidate
of I-Not_AE_Candidate
suicide I-Not_AE_Candidate
, O
bipolar B-Not_AE_Candidate
disorder I-Not_AE_Candidate
, O
and O
depression B-Not_AE_Candidate
. O

It O
should O
be O
noted O
that O
REMERON O
( O
mirtazapine O
) O
Tablets O
are O
not O
approved O
for O
use O
in O
treating O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
. O

Agranulocytosis O
In O
premarketing O
clinical O
trials O
, O
2 O
( O
1 O
with O
Sjogren B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
Syndrome I-Not_AE_Candidate
) O
out O
of O
2796 O
patients O
treated O
with O
REMERON O
( O
mirtazapine O
) O
Tablets O
developed O
agranulocytosis B-OSE_Labeled_AE
[ O
absolute B-OSE_Labeled_AE
neutrophil I-OSE_Labeled_AE
count I-OSE_Labeled_AE
( I-OSE_Labeled_AE
ANC I-OSE_Labeled_AE
) I-OSE_Labeled_AE
< I-OSE_Labeled_AE
5 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
mm I-OSE_Labeled_AE
3 I-OSE_Labeled_AE
with O
associated O
signs O
and O
symptoms O
, O
e.g. O
, O
fever B-NonOSE_AE
, O
infection B-NonOSE_AE
, O
etc O
. O
] O

and O
a O
third O
patient O
developed O
severe O
neutropenia B-OSE_Labeled_AE
( O
ANC B-OSE_Labeled_AE
< I-OSE_Labeled_AE
5 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
mm I-OSE_Labeled_AE
3 I-OSE_Labeled_AE
without O
any O
associated O
symptoms O
) O
. O

For O
these O
3 O
patients O
, O
onset O
of O
severe O
neutropenia B-OSE_Labeled_AE
was O
detected O
on O
days O
61 O
, O
9 O
, O
and O
14 O
of O
treatment O
, O
respectively O
. O

All O
3 O
patients O
recovered O
after O
REMERON O
was O
stopped O
. O

These O
3 O
cases O
yield O
a O
crude O
incidence O
of O
severe O
neutropenia B-OSE_Labeled_AE
( O
with O
or O
without O
associated O
infection O
) O
of O
approximately O
1.1 O
per O
thousand O
patients O
exposed O
, O
with O
a O
very O
wide O
95 O
% O
confidence O
interval O
, O
i.e. O
, O
2.2 O
cases O
per O
10,000 O
to O
3.1 O
cases O
per O
1000 O
. O

If O
a O
patient O
develops O
a O
sore B-NonOSE_AE
throat I-NonOSE_AE
, O
fever B-NonOSE_AE
, O
stomatitis B-NonOSE_AE
, O
or O
other O
signs O
of O
infection B-NonOSE_AE
, O
along O
with O
a O
low B-NonOSE_AE
WBC I-NonOSE_AE
count I-NonOSE_AE
, O
treatment O
with O
REMERON O
should O
be O
discontinued O
and O
the O
patient O
should O
be O
closely O
monitored O
. O

Serotonin O
Syndrome O
The O
development O
of O
a O
potentially O
life-threatening O
serotonin B-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
has O
been O
reported O
with O
SNRIs O
and O
SSRIs O
, O
including O
REMERON O
, O
alone O
but O
particularly O
with O
concomitant O
use O
of O
other O
serotonergic O
drugs O
( O
including O
triptans O
, O
tricyclic O
antidepressants O
, O
fentanyl O
, O
lithium O
, O
tramadol O
, O
tryptophan O
, O
buspirone O
, O
and O
St O
. O
John O
's O
wort O
) O
, O
and O
with O
drugs O
that O
impair O
metabolism O
of O
serotonin O
( O
in O
particular O
, O
MAOIs O
, O
both O
those O
intended O
to O
treat O
psychiatric O
disorders O
and O
also O
others O
, O
such O
as O
linezolid O
and O
intravenous O
methylene O
blue O
) O
. O

Serotonin B-NonOSE_AE
syndrome I-NonOSE_AE
symptoms O
may O
include O
mental B-NonOSE_AE
status I-NonOSE_AE
changes I-NonOSE_AE
( O
e.g. O
, O
agitation B-NonOSE_AE
, O
hallucinations B-NonOSE_AE
, O
delirium B-NonOSE_AE
, O
and O
coma B-NonOSE_AE
) O
, O
autonomic B-NonOSE_AE
instability I-NonOSE_AE
( O
e.g. O
, O
tachycardia B-NonOSE_AE
, O
labile B-NonOSE_AE
blood I-NonOSE_AE
pressure I-NonOSE_AE
, O
dizziness B-NonOSE_AE
, O
diaphoresis B-NonOSE_AE
, O
flushing B-NonOSE_AE
, O
hyperthermia B-NonOSE_AE
) O
, O
neuromuscular B-NonOSE_AE
symptoms I-NonOSE_AE
( O
e.g. O
, O
tremor B-NonOSE_AE
, O
rigidity B-NonOSE_AE
, O
myoclonus B-NonOSE_AE
, O
hyperreflexia B-NonOSE_AE
, O
incoordination B-NonOSE_AE
) O
, O
seizures B-NonOSE_AE
, O
and/or O
gastrointestinal B-NonOSE_AE
symptoms I-NonOSE_AE
( O
e.g. O
, O
nausea B-NonOSE_AE
, O
vomiting B-NonOSE_AE
, O
diarrhea B-NonOSE_AE
) O
. O

Patients O
should O
be O
monitored O
for O
the O
emergence O
of O
serotonin B-NonOSE_AE
syndrome I-NonOSE_AE
. O

The O
concomitant O
use O
of O
REMERON O
with O
MAOIs O
intended O
to O
treat O
psychiatric B-Not_AE_Candidate
disorders I-Not_AE_Candidate
is O
contraindicated O
. O

REMERON O
should O
also O
not O
be O
started O
in O
a O
patient O
who O
is O
being O
treated O
with O
MAOIs O
such O
as O
linezolid O
or O
intravenous O
methylene O
blue O
. O

All O
reports O
with O
methylene O
blue O
that O
provided O
information O
on O
the O
route O
of O
administration O
involved O
intravenous O
administration O
in O
the O
dose O
range O
of O
1 O
mg/kg O
to O
8 O
mg/kg O
. O

No O
reports O
involved O
the O
administration O
of O
methylene O
blue O
by O
other O
routes O
( O
such O
as O
oral O
tablets O
or O
local O
tissue O
injection O
) O
or O
at O
lower O
doses O
. O

There O
may O
be O
circumstances O
when O
it O
is O
necessary O
to O
initiate O
treatment O
with O
an O
MAOI O
such O
as O
linezolid O
or O
intravenous O
methylene O
blue O
in O
a O
patient O
taking O
REMERON O
. O

REMERON O
should O
be O
discontinued O
before O
initiating O
treatment O
with O
the O
MAOI O
( O
see O
CONTRAINDICATIONS O
and O
DOSAGE O
AND O
ADMINISTRATION O
) O
. O

If O
concomitant O
use O
of O
REMERON O
with O
other O
serotonergic O
drugs O
, O
including O
triptans O
, O
tricyclic O
antidepressants O
, O
fentanyl O
, O
lithium O
, O
tramadol O
, O
buspirone O
, O
tryptophan O
, O
and O
St O
. O
John O
's O
wort O
, O
is O
clinically O
warranted O
, O
be O
aware O
of O
a O
potential O
increased O
risk O
for O
serotonin B-NonOSE_AE
syndrome I-NonOSE_AE
, O
particularly O
during O
treatment O
initiation O
and O
dose O
increases O
. O

Treatment O
with O
REMERON O
and O
any O
concomitant O
serotonergic O
agents O
should O
be O
discontinued O
immediately O
if O
the O
above O
events O
occur O
and O
supportive O
symptomatic O
treatment O
should O
be O
initiated O
. O

Angle-Closure O
Glaucoma O
The O
pupillary B-OSE_Labeled_AE
dilation I-OSE_Labeled_AE
that O
occurs O
following O
use O
of O
many O
antidepressant O
drugs O
including O
REMERON O
may O
trigger O
an O
angle B-OSE_Labeled_AE
- I-OSE_Labeled_AE
closure I-OSE_Labeled_AE
attack I-OSE_Labeled_AE
in O
a O
patient O
with O
anatomically B-Not_AE_Candidate
narrow I-Not_AE_Candidate
angles I-Not_AE_Candidate
who O
does O
not O
have O
a O
patent O
iridectomy O
. O

QT O
Prolongation O
and O
Torsades O
de O
Pointes O
The O
effect B-NonOSE_AE
of O
REMER O
ON I-NonOSE_AE
( O
mirtazapine O
) O
on O
QTc I-NonOSE_AE
interval I-NonOSE_AE
was O
assessed O
in O
a O
clinical O
randomized O
trial O
with O
placebo O
and O
positive O
( O
moxifloxacin O
) O
controls O
involving O
54 O
healthy O
volunteers O
using O
exposure O
response O
analysis O
. O

This O
trial O
showed O
a O
positive O
relationship O
between O
mirtazapine O
concentrations O
and O
prolongation B-OSE_Labeled_AE
of I-OSE_Labeled_AE
the I-OSE_Labeled_AE
QTc I-OSE_Labeled_AE
interval I-OSE_Labeled_AE
. O

However O
, O
the O
degree O
of O
QT B-NonOSE_AE
prolongation I-NonOSE_AE
observed O
with O
both O
45 O
mg O
( O
therapeutic O
) O
and O
75 O
mg O
( O
supratherapeutic O
) O
doses O
of O
mirtazapine O
was O
not O
at O
a O
level O
generally O
considered O
to O
be O
clinically O
meaningful O
. O

During O
the O
postmarketing O
use O
of O
mirtazapine O
, O
cases O
of O
QT B-OSE_Labeled_AE
prolongation I-OSE_Labeled_AE
, O
Torsades B-OSE_Labeled_AE
de I-OSE_Labeled_AE
Pointes I-OSE_Labeled_AE
, O
ventricular B-OSE_Labeled_AE
tachycardia I-OSE_Labeled_AE
, O
and O
sudden B-OSE_Labeled_AE
death I-OSE_Labeled_AE
, O
have O
been O
reported O
( O
see O
ADVERSE O
REACTIONS O
) O
. O

The O
majority O
of O
reports O
occurred O
in O
association O
with O
overdose B-NonOSE_AE
or O
in O
patients O
with O
other O
risk O
factors O
for O
QT B-NonOSE_AE
prolongation I-NonOSE_AE
, O
including O
concomitant O
use O
of O
QTc B-NonOSE_AE
- I-NonOSE_AE
prolonging I-NonOSE_AE
medicines O
( O
see O
PRECAUTIONS O
, O
Drug O
Interactions O
and O
OVERDOSE O
sections O
) O
. O

Caution O
should O
be O
exercised O
when O
REMERON O
is O
prescribed O
in O
patients O
with O
known O
cardiovascular B-Not_AE_Candidate
disease I-Not_AE_Candidate
or O
family O
history O
of O
QT B-Not_AE_Candidate
prolongation I-Not_AE_Candidate
, O
and O
in O
concomitant O
use O
with O
other O
medicinal O
products O
thought O
to O
prolong B-NonOSE_AE
the I-NonOSE_AE
QTc I-NonOSE_AE
interval I-NonOSE_AE
. O

